In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzon: The Perils of Profitability

Executive Summary

Profitable but pipeline-poor Enzon tried to build a road back to R&D. But its value-oriented investors wouldn't support the spending ambitions, particularly as their royalty income declined. Enzon tried to merge with NPS, a pipeline-rich unprofitable company, hoping to transform its conservative shareholder base for one looking for biopharma-type home runs--but there too ran smack into the immovable force of investor inertia.
Advertisement

Related Content

20% Solution: Addressing the Biotech/Pharma Logjam with Innovation Partnerships
Reliant: The Expensive Opportunities in Primary Care
Hep C Development Dilemma: Big Money Now or Bigger Money Later?
ViroPharma's Second Act: First a Tough One to Follow
Symphony & Guilford Try Out Project Financing
Are Late-Stage Deals Beginning to Lose Their Luster?
What's a Marketed Drug Worth?
What's a Marketed Drug Worth?
Opportunity Cost: How Alkermes Plans to Survive the Long Winter
Alkermes' Incrementalism

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV002321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel